Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGN-ES001 in Chronic Widespread Pain/Fibromyalgia
NCT03058224Completed
- Sponsor
- IgNova
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial in Chronic widespread pain (CWP) and fibromyalgia (FM) comparing IGN-ES001 with Placebo (2 arms). Primary endpoints: Pain, final percent changes from baseline at 6 weeks and Pain, final responder at 6 weeks. Started Feb 2017; status: completed.
02
Drugs
ES001
03
Conditions
Chronic widespread pain (CWP)fibromyalgia (FM)
Beyond the preview
Go deeper on NCT03058224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058224.